Biotech Struggles to Recover in 2024
Biotech valuations and investing peaked in late 2021, with investors surging into the sector at the height of the Covid-19 pandemic. Interest in the sector waned over the last few years — due in part to sharply increased interest rates and the rapid emergence of the AI mega trend. But now, the smart money is starting to flow back into the
sector…
